Duration from seroconversion to eligibility for antiretroviral therapy and from ART eligibility to death in adult HIV-infected patients from low and middle-income countries: collaborative analysis of prospective studies
Identifieur interne : 001D73 ( Istex/Corpus ); précédent : 001D72; suivant : 001D74Duration from seroconversion to eligibility for antiretroviral therapy and from ART eligibility to death in adult HIV-infected patients from low and middle-income countries: collaborative analysis of prospective studies
Auteurs :Source :
- Sexually Transmitted Infections [ 1368-4973 ] ; 2008-08.
English descriptors
- KwdEn :
- Active antiretroviral therapy, Additional analysis, Aids rangsin, Alpha network, Antiretroviral, Antiretroviral therapy, Available information, Blood donors, Cell count, Clinical stage, Cohort, Collaborative analysis, Community cohort, Confidence interval, Confidence intervals, Consistency constraint, Cote, Cotrimoxazole prophylaxis, Credibility, Credibility interval, Credibility intervals, Different eligibility criteria, Disease progression, Eligibility, Eligibility criteria, Estimate coverage, Exact date, First time, Hazard ratios, Individual participant data, Individual patient data, Literature review, Male blood donors, Median, Median duration, Model parameters, Mortality patterns, Nations programme, Natural history, Northern thailand, Preventive medicine, Public health approach, Random effects, Relevant criteria, Rural uganda, Seroconversion, Seroconverter cohorts, Survival distributions, Survival times, Systematic reviews, Thai, Thai cohorts, Thai studies, Thailand, Time intervals, Time points, Total time, Transm, Treatment eligibility, Uganda, Universal access, World health organization, Years years.
- Teeft :
- Active antiretroviral therapy, Additional analysis, Aids rangsin, Alpha network, Antiretroviral, Antiretroviral therapy, Available information, Blood donors, Cell count, Clinical stage, Cohort, Collaborative analysis, Community cohort, Confidence interval, Confidence intervals, Consistency constraint, Cote, Cotrimoxazole prophylaxis, Credibility, Credibility interval, Credibility intervals, Different eligibility criteria, Disease progression, Eligibility, Eligibility criteria, Estimate coverage, Exact date, First time, Hazard ratios, Individual participant data, Individual patient data, Literature review, Male blood donors, Median, Median duration, Model parameters, Mortality patterns, Nations programme, Natural history, Northern thailand, Preventive medicine, Public health approach, Random effects, Relevant criteria, Rural uganda, Seroconversion, Seroconverter cohorts, Survival distributions, Survival times, Systematic reviews, Thai, Thai cohorts, Thai studies, Thailand, Time intervals, Time points, Total time, Transm, Treatment eligibility, Uganda, Universal access, World health organization, Years years.
Abstract
Background: Estimation of the number of people in need of antiretroviral therapy (ART) in resource-limited settings requires information on the time from seroconversion to ART eligibility and from ART eligibility to death. Objectives: To estimate duration from seroconversion to different ART eligibility criteria and from ART eligibility to death in HIV-infected adults in low-income and middle-income countries. Methods: Participants with documented seroconversion from five cohorts (two cohorts from Uganda, two from Thailand and one from Côte d’Ivoire) were analysed. We used Weibull survival models and Bayesian simulation methods to model true (unobserved) first time of treatment eligibility. We set a consistency constraint so that the mean duration from seroconversion to death was equal to the mean from seroconversion to ART eligibility plus the mean from eligibility to death. Results: We analysed data from 2072 participants, 16 157 person-years of follow-up and 794 deaths. For the criterion CD4 T-lymphocyte count <200 cells ×106/l, the median duration from seroconversion to ART eligibility was 6.1 years (95% credibility interval 3.3–10.4) for all studies and 7.6 years (95% credibility interval 3.4–15.2) for all but the Thai cohorts. Corresponding estimates for the time from CD4 T-lymphocyte count <200 cells ×106/l to death were 2.1 years (0.7–4.8) and 2.7 years (0.8–8.4). When including all cohorts, the mean time from serconversion to CD4 T-lymphocyte count <200 cells ×106/l and from CD4 T-lymphocyte count <200 cells ×106/l to death represented 66% (38–87%) and 34% (13–62%), respectively of the total survival time. Conclusions: The duration of different ART eligibility criteria to death was longer than the estimates used in previous calculations of the number of people needing ART. However, uncertainty in estimates was considerable and heterogeneity across cohorts important.
Url:
DOI: 10.1136/sti.2008.029793
Links to Exploration step
ISTEX:5B0FC4367EF7D228FCD6D15EF0EF28970A0AA655Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Duration from seroconversion to eligibility for antiretroviral therapy and from ART eligibility to death in adult HIV-infected patients from low and middle-income countries: collaborative analysis of prospective studies</title></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:5B0FC4367EF7D228FCD6D15EF0EF28970A0AA655</idno><date when="2008" year="2008">2008</date><idno type="doi">10.1136/sti.2008.029793</idno><idno type="url">https://api.istex.fr/document/5B0FC4367EF7D228FCD6D15EF0EF28970A0AA655/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001D73</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001D73</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Duration from seroconversion to eligibility for antiretroviral therapy and from ART eligibility to death in adult HIV-infected patients from low and middle-income countries: collaborative analysis of prospective studies</title></analytic><monogr></monogr><series><title level="j">Sexually Transmitted Infections</title><title level="j" type="abbrev">Sex Transm Infect</title><idno type="ISSN">1368-4973</idno><idno type="eISSN">1472-3263</idno><imprint><publisher>BMJ Publishing Group Ltd</publisher><date type="published" when="2008-08">2008-08</date><biblScope unit="volume">84</biblScope><biblScope unit="issue">Suppl 1</biblScope><biblScope unit="page" from="31">i31</biblScope></imprint><idno type="ISSN">1368-4973</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1368-4973</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Active antiretroviral therapy</term><term>Additional analysis</term><term>Aids rangsin</term><term>Alpha network</term><term>Antiretroviral</term><term>Antiretroviral therapy</term><term>Available information</term><term>Blood donors</term><term>Cell count</term><term>Clinical stage</term><term>Cohort</term><term>Collaborative analysis</term><term>Community cohort</term><term>Confidence interval</term><term>Confidence intervals</term><term>Consistency constraint</term><term>Cote</term><term>Cotrimoxazole prophylaxis</term><term>Credibility</term><term>Credibility interval</term><term>Credibility intervals</term><term>Different eligibility criteria</term><term>Disease progression</term><term>Eligibility</term><term>Eligibility criteria</term><term>Estimate coverage</term><term>Exact date</term><term>First time</term><term>Hazard ratios</term><term>Individual participant data</term><term>Individual patient data</term><term>Literature review</term><term>Male blood donors</term><term>Median</term><term>Median duration</term><term>Model parameters</term><term>Mortality patterns</term><term>Nations programme</term><term>Natural history</term><term>Northern thailand</term><term>Preventive medicine</term><term>Public health approach</term><term>Random effects</term><term>Relevant criteria</term><term>Rural uganda</term><term>Seroconversion</term><term>Seroconverter cohorts</term><term>Survival distributions</term><term>Survival times</term><term>Systematic reviews</term><term>Thai</term><term>Thai cohorts</term><term>Thai studies</term><term>Thailand</term><term>Time intervals</term><term>Time points</term><term>Total time</term><term>Transm</term><term>Treatment eligibility</term><term>Uganda</term><term>Universal access</term><term>World health organization</term><term>Years years</term></keywords><keywords scheme="Teeft" xml:lang="en"><term>Active antiretroviral therapy</term><term>Additional analysis</term><term>Aids rangsin</term><term>Alpha network</term><term>Antiretroviral</term><term>Antiretroviral therapy</term><term>Available information</term><term>Blood donors</term><term>Cell count</term><term>Clinical stage</term><term>Cohort</term><term>Collaborative analysis</term><term>Community cohort</term><term>Confidence interval</term><term>Confidence intervals</term><term>Consistency constraint</term><term>Cote</term><term>Cotrimoxazole prophylaxis</term><term>Credibility</term><term>Credibility interval</term><term>Credibility intervals</term><term>Different eligibility criteria</term><term>Disease progression</term><term>Eligibility</term><term>Eligibility criteria</term><term>Estimate coverage</term><term>Exact date</term><term>First time</term><term>Hazard ratios</term><term>Individual participant data</term><term>Individual patient data</term><term>Literature review</term><term>Male blood donors</term><term>Median</term><term>Median duration</term><term>Model parameters</term><term>Mortality patterns</term><term>Nations programme</term><term>Natural history</term><term>Northern thailand</term><term>Preventive medicine</term><term>Public health approach</term><term>Random effects</term><term>Relevant criteria</term><term>Rural uganda</term><term>Seroconversion</term><term>Seroconverter cohorts</term><term>Survival distributions</term><term>Survival times</term><term>Systematic reviews</term><term>Thai</term><term>Thai cohorts</term><term>Thai studies</term><term>Thailand</term><term>Time intervals</term><term>Time points</term><term>Total time</term><term>Transm</term><term>Treatment eligibility</term><term>Uganda</term><term>Universal access</term><term>World health organization</term><term>Years years</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract">Background: Estimation of the number of people in need of antiretroviral therapy (ART) in resource-limited settings requires information on the time from seroconversion to ART eligibility and from ART eligibility to death. Objectives: To estimate duration from seroconversion to different ART eligibility criteria and from ART eligibility to death in HIV-infected adults in low-income and middle-income countries. Methods: Participants with documented seroconversion from five cohorts (two cohorts from Uganda, two from Thailand and one from Côte d’Ivoire) were analysed. We used Weibull survival models and Bayesian simulation methods to model true (unobserved) first time of treatment eligibility. We set a consistency constraint so that the mean duration from seroconversion to death was equal to the mean from seroconversion to ART eligibility plus the mean from eligibility to death. Results: We analysed data from 2072 participants, 16 157 person-years of follow-up and 794 deaths. For the criterion CD4 T-lymphocyte count <200 cells ×106/l, the median duration from seroconversion to ART eligibility was 6.1 years (95% credibility interval 3.3–10.4) for all studies and 7.6 years (95% credibility interval 3.4–15.2) for all but the Thai cohorts. Corresponding estimates for the time from CD4 T-lymphocyte count <200 cells ×106/l to death were 2.1 years (0.7–4.8) and 2.7 years (0.8–8.4). When including all cohorts, the mean time from serconversion to CD4 T-lymphocyte count <200 cells ×106/l and from CD4 T-lymphocyte count <200 cells ×106/l to death represented 66% (38–87%) and 34% (13–62%), respectively of the total survival time. Conclusions: The duration of different ART eligibility criteria to death was longer than the estimates used in previous calculations of the number of people needing ART. However, uncertainty in estimates was considerable and heterogeneity across cohorts important.</div></front></TEI><istex><corpusName>bmj</corpusName><keywords><teeft><json:string>seroconversion</json:string><json:string>cohort</json:string><json:string>antiretroviral</json:string><json:string>uganda</json:string><json:string>antiretroviral therapy</json:string><json:string>treatment eligibility</json:string><json:string>eligibility</json:string><json:string>median</json:string><json:string>cote</json:string><json:string>eligibility criteria</json:string><json:string>transm</json:string><json:string>thai</json:string><json:string>first time</json:string><json:string>thai cohorts</json:string><json:string>clinical stage</json:string><json:string>rural uganda</json:string><json:string>credibility</json:string><json:string>individual participant data</json:string><json:string>collaborative analysis</json:string><json:string>credibility intervals</json:string><json:string>natural history</json:string><json:string>median duration</json:string><json:string>disease progression</json:string><json:string>additional analysis</json:string><json:string>seroconverter cohorts</json:string><json:string>credibility interval</json:string><json:string>world health organization</json:string><json:string>systematic reviews</json:string><json:string>blood donors</json:string><json:string>survival times</json:string><json:string>active antiretroviral therapy</json:string><json:string>consistency constraint</json:string><json:string>exact date</json:string><json:string>survival distributions</json:string><json:string>random effects</json:string><json:string>time points</json:string><json:string>cell count</json:string><json:string>estimate coverage</json:string><json:string>confidence intervals</json:string><json:string>male blood donors</json:string><json:string>community cohort</json:string><json:string>universal access</json:string><json:string>different eligibility criteria</json:string><json:string>time intervals</json:string><json:string>total time</json:string><json:string>model parameters</json:string><json:string>hazard ratios</json:string><json:string>available information</json:string><json:string>alpha network</json:string><json:string>years years</json:string><json:string>mortality patterns</json:string><json:string>confidence interval</json:string><json:string>cotrimoxazole prophylaxis</json:string><json:string>thai studies</json:string><json:string>nations programme</json:string><json:string>literature review</json:string><json:string>public health approach</json:string><json:string>individual patient data</json:string><json:string>preventive medicine</json:string><json:string>aids rangsin</json:string><json:string>northern thailand</json:string><json:string>relevant criteria</json:string><json:string>thailand</json:string></teeft></keywords><articleId><json:string>st29793</json:string></articleId><language><json:string>eng</json:string></language><originalGenre><json:string>research-article</json:string></originalGenre><abstract>Background: Estimation of the number of people in need of antiretroviral therapy (ART) in resource-limited settings requires information on the time from seroconversion to ART eligibility and from ART eligibility to death. Objectives: To estimate duration from seroconversion to different ART eligibility criteria and from ART eligibility to death in HIV-infected adults in low-income and middle-income countries. Methods: Participants with documented seroconversion from five cohorts (two cohorts from Uganda, two from Thailand and one from Côte d’Ivoire) were analysed. We used Weibull survival models and Bayesian simulation methods to model true (unobserved) first time of treatment eligibility. We set a consistency constraint so that the mean duration from seroconversion to death was equal to the mean from seroconversion to ART eligibility plus the mean from eligibility to death. Results: We analysed data from 2072 participants, 16 157 person-years of follow-up and 794 deaths. For the criterion CD4 T-lymphocyte count >200 cells ×106/l, the median duration from seroconversion to ART eligibility was 6.1 years (95% credibility interval 3.3–10.4) for all studies and 7.6 years (95% credibility interval 3.4–15.2) for all but the Thai cohorts. Corresponding estimates for the time from CD4 T-lymphocyte count >200 cells ×106/l to death were 2.1 years (0.7–4.8) and 2.7 years (0.8–8.4). When including all cohorts, the mean time from serconversion to CD4 T-lymphocyte count >200 cells ×106/l and from CD4 T-lymphocyte count >200 cells ×106/l to death represented 66% (38–87%) and 34% (13–62%), respectively of the total survival time. Conclusions: The duration of different ART eligibility criteria to death was longer than the estimates used in previous calculations of the number of people needing ART. However, uncertainty in estimates was considerable and heterogeneity across cohorts important.</abstract><qualityIndicators><score>6.925</score><pdfVersion>1.2</pdfVersion><pdfPageSize>595.276 x 793.701 pts</pdfPageSize><refBibsNative>false</refBibsNative><keywordCount>0</keywordCount><abstractCharCount>1907</abstractCharCount><pdfWordCount>3925</pdfWordCount><pdfCharCount>26698</pdfCharCount><pdfPageCount>6</pdfPageCount><abstractWordCount>279</abstractWordCount></qualityIndicators><title>Duration from seroconversion to eligibility for antiretroviral therapy and from ART eligibility to death in adult HIV-infected patients from low and middle-income countries: collaborative analysis of prospective studies</title><pmid><json:string>18647863</json:string></pmid><corporate><json:item><name>The eligibility for ART in lower income countries (eART-linc) collaboration</name></json:item></corporate><genre><json:string>research-article</json:string></genre><host><title>Sexually Transmitted Infections</title><language><json:string>unknown</json:string></language><issn><json:string>1368-4973</json:string></issn><eissn><json:string>1472-3263</json:string></eissn><publisherId><json:string>sti</json:string></publisherId><volume>84</volume><issue>Suppl 1</issue><pages><first>i31</first></pages><genre><json:string>journal</json:string></genre></host><categories><wos><json:string>science</json:string><json:string>infectious diseases</json:string></wos><scienceMetrix><json:string>health sciences</json:string><json:string>public health & health services</json:string><json:string>public health</json:string></scienceMetrix><inist><json:string>sciences appliquees, technologies et medecines</json:string><json:string>sciences biologiques et medicales</json:string><json:string>sciences medicales</json:string></inist></categories><publicationDate>2008</publicationDate><copyrightDate>2008</copyrightDate><doi><json:string>10.1136/sti.2008.029793</json:string></doi><id>5B0FC4367EF7D228FCD6D15EF0EF28970A0AA655</id><score>1</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/document/5B0FC4367EF7D228FCD6D15EF0EF28970A0AA655/fulltext/pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/document/5B0FC4367EF7D228FCD6D15EF0EF28970A0AA655/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/5B0FC4367EF7D228FCD6D15EF0EF28970A0AA655/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Duration from seroconversion to eligibility for antiretroviral therapy and from ART eligibility to death in adult HIV-infected patients from low and middle-income countries: collaborative analysis of prospective studies</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher scheme="https://publisher-list.data.istex.fr">BMJ Publishing Group Ltd</publisher><availability><licence><p>2008 BMJ Publishing Group Ltd</p></licence><p scheme="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-7M42M2QJ-2">bmj</p></availability><date>2008-07-22</date></publicationStmt><notesStmt><note type="research-article" scheme="https://content-type.data.istex.fr/ark:/67375/XTP-1JC4F85T-7">research-article</note><note type="journal" scheme="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Duration from seroconversion to eligibility for antiretroviral therapy and from ART eligibility to death in adult HIV-infected patients from low and middle-income countries: collaborative analysis of prospective studies</title><author role="org"><orgName>The eligibility for ART in lower income countries (eART-linc) collaboration</orgName><affiliation>Dr Marcel Zwahlen, Institute of Social and Preventive Medicine (ISPM), University of Bern, Finkenhubelweg 11, CH-3012 Bern, Switzerland; eART-linc@ispm.unibe.ch</affiliation></author><idno type="istex">5B0FC4367EF7D228FCD6D15EF0EF28970A0AA655</idno><idno type="ark">ark:/67375/NVC-LGV47DPB-D</idno><idno type="DOI">10.1136/sti.2008.029793</idno><idno type="href">sextrans-84-i31.pdf</idno><idno type="article-id">st29793</idno><idno type="PMID">18647863</idno><idno type="local">sextrans;84/Suppl_1/i31</idno></analytic><monogr><title level="j">Sexually Transmitted Infections</title><title level="j" type="abbrev">Sex Transm Infect</title><idno type="pISSN">1368-4973</idno><idno type="eISSN">1472-3263</idno><idno type="publisher-id">sti</idno><idno type="PublisherID-hwp">sextrans</idno><idno type="PublisherID-nlm-ta">Sex Transm Infect</idno><imprint><publisher>BMJ Publishing Group Ltd</publisher><date type="published" when="2008-08"></date><biblScope unit="volume">84</biblScope><biblScope unit="issue">Suppl 1</biblScope><biblScope unit="page" from="31">i31</biblScope></imprint></monogr></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2008-07-22</date></creation><langUsage><language ident="en">en</language></langUsage><abstract><p>Background: Estimation of the number of people in need of antiretroviral therapy (ART) in resource-limited settings requires information on the time from seroconversion to ART eligibility and from ART eligibility to death. Objectives: To estimate duration from seroconversion to different ART eligibility criteria and from ART eligibility to death in HIV-infected adults in low-income and middle-income countries. Methods: Participants with documented seroconversion from five cohorts (two cohorts from Uganda, two from Thailand and one from Côte d’Ivoire) were analysed. We used Weibull survival models and Bayesian simulation methods to model true (unobserved) first time of treatment eligibility. We set a consistency constraint so that the mean duration from seroconversion to death was equal to the mean from seroconversion to ART eligibility plus the mean from eligibility to death. Results: We analysed data from 2072 participants, 16 157 person-years of follow-up and 794 deaths. For the criterion CD4 T-lymphocyte count <200 cells ×106/l, the median duration from seroconversion to ART eligibility was 6.1 years (95% credibility interval 3.3–10.4) for all studies and 7.6 years (95% credibility interval 3.4–15.2) for all but the Thai cohorts. Corresponding estimates for the time from CD4 T-lymphocyte count <200 cells ×106/l to death were 2.1 years (0.7–4.8) and 2.7 years (0.8–8.4). When including all cohorts, the mean time from serconversion to CD4 T-lymphocyte count <200 cells ×106/l and from CD4 T-lymphocyte count <200 cells ×106/l to death represented 66% (38–87%) and 34% (13–62%), respectively of the total survival time. Conclusions: The duration of different ART eligibility criteria to death was longer than the estimates used in previous calculations of the number of people needing ART. However, uncertainty in estimates was considerable and heterogeneity across cohorts important.</p></abstract></profileDesc><revisionDesc><change when="2008-07-22">Created</change><change when="2008-08">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/document/5B0FC4367EF7D228FCD6D15EF0EF28970A0AA655/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="corpus bmj" wicri:toSee="no header"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="no"</istex:xmlDeclaration><istex:docType PUBLIC="-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" URI="archivearticle.dtd" name="istex:docType"></istex:docType><istex:document><article article-type="research-article" xml:lang="EN"><front><journal-meta><journal-id journal-id-type="hwp">sextrans</journal-id><journal-id journal-id-type="nlm-ta">Sex Transm Infect</journal-id><journal-id journal-id-type="publisher-id">sti</journal-id><journal-title>Sexually Transmitted Infections</journal-title><abbrev-journal-title abbrev-type="publisher">Sex Transm Infect</abbrev-journal-title><issn pub-type="ppub">1368-4973</issn><issn pub-type="epub">1472-3263</issn><publisher><publisher-name>BMJ Publishing Group Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">st29793</article-id><article-id pub-id-type="doi">10.1136/sti.2008.029793</article-id><article-id pub-id-type="other">sextrans;84/Suppl_1/i31</article-id><article-id pub-id-type="pmid">18647863</article-id><article-id pub-id-type="other">i31</article-id><article-id pub-id-type="other">sti.2008.029793</article-id><article-categories><subj-group subj-group-type="heading"><subject>Supplement</subject></subj-group></article-categories><title-group><article-title>Duration from seroconversion to eligibility for antiretroviral therapy and from ART eligibility to death in adult HIV-infected patients from low and middle-income countries: collaborative analysis of prospective studies</article-title><alt-title alt-title-type="running-head">Supplement</alt-title></title-group><contrib-group><contrib xlink:type="simple"><collab xlink:type="simple">The eligibility for ART in lower income countries (eART-linc) collaboration</collab></contrib></contrib-group><author-notes><corresp>Dr Marcel Zwahlen, Institute of Social and Preventive Medicine (ISPM), University of Bern, Finkenhubelweg 11, CH-3012 Bern, Switzerland; <email xlink:type="simple">eART-linc@ispm.unibe.ch</email></corresp></author-notes><pub-date pub-type="ppub"><month>8</month><year>2008</year></pub-date><pub-date pub-type="epub"><day>22</day><month>7</month><year>2008</year></pub-date><volume>84</volume><volume-id pub-id-type="other">84</volume-id><volume-id pub-id-type="other">84</volume-id><issue>Suppl 1</issue><issue-id pub-id-type="other">sextrans;84/Suppl_1</issue-id><issue-id pub-id-type="other" content-type="supplement">Suppl_1</issue-id><issue-id pub-id-type="other">84/Suppl_1</issue-id><issue-title>Improved data, methods and tools for the 2007 HIV and AIDS estimates and projections</issue-title><fpage>i31</fpage><history><date date-type="accepted"><day>13</day><month>5</month><year>2008</year></date></history><permissions><copyright-statement>2008 BMJ Publishing Group Ltd</copyright-statement><copyright-year>2008</copyright-year><license license-type="open-access" xlink:type="simple"><p></p></license></permissions><self-uri content-type="pdf" xlink:role="full-text" xlink:href="sextrans-84-i31.pdf"></self-uri><abstract><sec><title>Background:</title><p>Estimation of the number of people in need of antiretroviral therapy (ART) in resource-limited settings requires information on the time from seroconversion to ART eligibility and from ART eligibility to death.</p></sec><sec><title>Objectives:</title><p>To estimate duration from seroconversion to different ART eligibility criteria and from ART eligibility to death in HIV-infected adults in low-income and middle-income countries.</p></sec><sec><title>Methods:</title><p>Participants with documented seroconversion from five cohorts (two cohorts from Uganda, two from Thailand and one from Côte d’Ivoire) were analysed. We used Weibull survival models and Bayesian simulation methods to model true (unobserved) first time of treatment eligibility. We set a consistency constraint so that the mean duration from seroconversion to death was equal to the mean from seroconversion to ART eligibility plus the mean from eligibility to death.</p></sec><sec><title>Results:</title><p>We analysed data from 2072 participants, 16 157 person-years of follow-up and 794 deaths. For the criterion CD4 T-lymphocyte count <200 cells ×10<sup>6</sup>/l, the median duration from seroconversion to ART eligibility was 6.1 years (95% credibility interval 3.3–10.4) for all studies and 7.6 years (95% credibility interval 3.4–15.2) for all but the Thai cohorts. Corresponding estimates for the time from CD4 T-lymphocyte count <200 cells ×10<sup>6</sup>/l to death were 2.1 years (0.7–4.8) and 2.7 years (0.8–8.4). When including all cohorts, the mean time from serconversion to CD4 T-lymphocyte count <200 cells ×10<sup>6</sup>/l and from CD4 T-lymphocyte count <200 cells ×10<sup>6</sup>/l to death represented 66% (38–87%) and 34% (13–62%), respectively of the total survival time.</p></sec><sec><title>Conclusions:</title><p>The duration of different ART eligibility criteria to death was longer than the estimates used in previous calculations of the number of people needing ART. However, uncertainty in estimates was considerable and heterogeneity across cohorts important.</p></sec></abstract></article-meta></front></article></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Duration from seroconversion to eligibility for antiretroviral therapy and from ART eligibility to death in adult HIV-infected patients from low and middle-income countries: collaborative analysis of prospective studies</title></titleInfo><titleInfo type="alternative" lang="en" contentType="CDATA"><title>Duration from seroconversion to eligibility for antiretroviral therapy and from ART eligibility to death in adult HIV-infected patients from low and middle-income countries: collaborative analysis of prospective studies</title></titleInfo><name type="corporate"><namePart>The eligibility for ART in lower income countries (eART-linc) collaboration</namePart><affiliation>Dr Marcel Zwahlen, Institute of Social and Preventive Medicine (ISPM), University of Bern, Finkenhubelweg 11, CH-3012 Bern, Switzerland; eART-linc@ispm.unibe.ch</affiliation></name><typeOfResource>text</typeOfResource><genre type="research-article" displayLabel="research-article" authority="ISTEX" authorityURI="https://content-type.data.istex.fr" valueURI="https://content-type.data.istex.fr/ark:/67375/XTP-1JC4F85T-7">research-article</genre><originInfo><publisher>BMJ Publishing Group Ltd</publisher><dateIssued encoding="w3cdtf">2008-08</dateIssued><dateCreated encoding="w3cdtf">2008-07-22</dateCreated><copyrightDate encoding="w3cdtf">2008</copyrightDate></originInfo><language><languageTerm type="code" authority="iso639-2b">eng</languageTerm><languageTerm type="code" authority="rfc3066">en</languageTerm></language><abstract>Background: Estimation of the number of people in need of antiretroviral therapy (ART) in resource-limited settings requires information on the time from seroconversion to ART eligibility and from ART eligibility to death. Objectives: To estimate duration from seroconversion to different ART eligibility criteria and from ART eligibility to death in HIV-infected adults in low-income and middle-income countries. Methods: Participants with documented seroconversion from five cohorts (two cohorts from Uganda, two from Thailand and one from Côte d’Ivoire) were analysed. We used Weibull survival models and Bayesian simulation methods to model true (unobserved) first time of treatment eligibility. We set a consistency constraint so that the mean duration from seroconversion to death was equal to the mean from seroconversion to ART eligibility plus the mean from eligibility to death. Results: We analysed data from 2072 participants, 16 157 person-years of follow-up and 794 deaths. For the criterion CD4 T-lymphocyte count <200 cells ×106/l, the median duration from seroconversion to ART eligibility was 6.1 years (95% credibility interval 3.3–10.4) for all studies and 7.6 years (95% credibility interval 3.4–15.2) for all but the Thai cohorts. Corresponding estimates for the time from CD4 T-lymphocyte count <200 cells ×106/l to death were 2.1 years (0.7–4.8) and 2.7 years (0.8–8.4). When including all cohorts, the mean time from serconversion to CD4 T-lymphocyte count <200 cells ×106/l and from CD4 T-lymphocyte count <200 cells ×106/l to death represented 66% (38–87%) and 34% (13–62%), respectively of the total survival time. Conclusions: The duration of different ART eligibility criteria to death was longer than the estimates used in previous calculations of the number of people needing ART. However, uncertainty in estimates was considerable and heterogeneity across cohorts important.</abstract><relatedItem type="host"><titleInfo><title>Sexually Transmitted Infections</title></titleInfo><titleInfo type="abbreviated"><title>Sex Transm Infect</title></titleInfo><genre type="journal" authority="ISTEX" authorityURI="https://publication-type.data.istex.fr" valueURI="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</genre><identifier type="ISSN">1368-4973</identifier><identifier type="eISSN">1472-3263</identifier><identifier type="PublisherID">sti</identifier><identifier type="PublisherID-hwp">sextrans</identifier><identifier type="PublisherID-nlm-ta">Sex Transm Infect</identifier><part><date>2008</date><detail type="title"><title>Improved data, methods and tools for the 2007 HIV and AIDS estimates and projections</title></detail><detail type="volume"><caption>vol.</caption><number>84</number></detail><detail type="issue"><caption>no.</caption><number>Suppl 1</number></detail><extent unit="pages"><start>i31</start></extent></part></relatedItem><identifier type="istex">5B0FC4367EF7D228FCD6D15EF0EF28970A0AA655</identifier><identifier type="ark">ark:/67375/NVC-LGV47DPB-D</identifier><identifier type="DOI">10.1136/sti.2008.029793</identifier><identifier type="href">sextrans-84-i31.pdf</identifier><identifier type="ArticleID">st29793</identifier><identifier type="PMID">18647863</identifier><identifier type="local">sextrans;84/Suppl_1/i31</identifier><accessCondition type="use and reproduction" contentType="copyright">2008 BMJ Publishing Group Ltd</accessCondition><recordInfo><recordContentSource authority="ISTEX" authorityURI="https://loaded-corpus.data.istex.fr" valueURI="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-7M42M2QJ-2">bmj</recordContentSource><recordOrigin>2008 BMJ Publishing Group Ltd</recordOrigin></recordInfo></mods><json:item><extension>json</extension><original>false</original><mimetype>application/json</mimetype><uri>https://api.istex.fr/document/5B0FC4367EF7D228FCD6D15EF0EF28970A0AA655/metadata/json</uri></json:item></metadata><annexes><json:item><extension>jpeg</extension><original>true</original><mimetype>image/jpeg</mimetype><uri>https://api.istex.fr/document/5B0FC4367EF7D228FCD6D15EF0EF28970A0AA655/annexes/jpeg</uri></json:item></annexes><author></author><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/SidaSubSaharaV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001D73 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 001D73 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= SidaSubSaharaV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:5B0FC4367EF7D228FCD6D15EF0EF28970A0AA655
|texte= Duration from seroconversion to eligibility for antiretroviral therapy and from ART eligibility to death in adult HIV-infected patients from low and middle-income countries: collaborative analysis of prospective studies
}}
| This area was generated with Dilib version V0.6.32. |  |